Second Genome and Evotec to collaborate on microbiome discovery and development
Second Genome and Evotec will screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec’s technology platform, chemical libraries and other preclinical capabilities
Evotec and Second Genome have announced a collaboration on small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec.
Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and results derived from Evotec’s integrated drug discovery platform.
As part of the collaboration, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec’s technology platform, chemical libraries and other preclinical capabilities.
The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for preclinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: ‘We are pleased to contribute to Second Genome’s unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut. The enrichment and maturation of Second Genome’s project portfolio through our contributions will enhance the Company’s clinical pipeline in the near future.’
Mohan Iyer, Chief Business Officer of Second Genome, added: ‘The partnership with Evotec allows us to efficiently translate our unique microbiome discovery platform into tangible drug molecules for clinical development. Our enriched pipeline offers new treatment approaches for patients across a wide range of diseases with an initial focus on inflammatory conditions. We look forward to a sustained partnership with Evotec.’
